Analytics 4 Life, a Toronto, Canada-based Research Triagle Park, NC-based digital health company, completed a $25m Series B financing.
The financing was supported by an international syndicate of accredited investors, including physicians, healthcare professionals, and medical device experts.
The company intends to use the funds to advance proprietary imaging technology designed to assess coronary artery disease.
Led by Don Crawford, CEO, Analytics 4 Life is a digital health company applying artificial intelligence to develop solutions that improve existing care pathways. The company’s novel cardiac imaging technology is under clinical investigation to help physicians assess the presence of coronary artery disease (CAD) using intrinsic signals scanned from the body without radiation, contrast agents, or cardiac stress.
The first application of this technology is CorVista™, a non-invasive, physician-directed diagnostic test that aims to identify the presence of CAD without radiation or cardiac stress.
CorVista is designed to scan signals naturally emitted by the body with a synchronous array of seven sensors on a proprietary collection device. After the signals are acquired, the signal package is instantaneously transmitted to the cloud where it is analyzed by a machine-learned algorithm to generate a unique image and a heart model indicating areas of potential heart disease associated with the presence of CAD. The results of the test are displayed on a secure physician web portal that, in combination with a patient’s medical history, risk factors, and symptoms, are used by the interpreting physician to recommend further treatment.
In addition to the funding, Aaron Berez, M.D., the founder and CEO of Alembic LLC, an early-stage medical device company, joined Analytics 4 Life’s Board.